Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
hfHZTR12cnYExB5Q
